DIRS.INFO The most relevant business & tech news

One of them said that the cut off point could be closer to 6 billion euros ($6.33 billion). Some analysts had already questioned Renault's hoped-for valuation of up to 10 billion euros, with some suggesting the carmaker should pursue alternative options to raise cash. De Meo said in September that the listing could value Ampere at between 8 and 10 billion euros, above the French carmaker's own current market capitalisation of 9.55 billion euros. Other EV makers have seen their market value fall sharply in recent months. The Ampere IPO would include a mix of Renault's shares and new shares and could happen as early as April 2024, one of the people said, depending on market conditions.

Persons: Gonzalo Fuentes, Ampere, France's, Tesla, Renault's, Luca de Meo, China's Geely, IPOs, De Meo, Bernstein, de Meo, Elon Musk's Tesla, Mathieu Rosemain, Silvia Aloisi, Pablo Mayo Cerqueiro, Gilles Guillaume, Anousha Sakoui, Alexander Smith Organizations: Renault, Viva Technology, Porte de, REUTERS, Reuters, DKV Mobility, HK, Saudi Arabia's Aramco, Nissan, IPOs Renault, EV, Commission, UBS, Barclays, Ampere, Mitsubishi, Thomson Locations: Porte, Paris, France, LONDON, China, Saudi, Europe, Ampere, Elon

ST. LOUIS (AP) — Ben Phillips’ childhood memories include basketball games with friends, and neighbors gathering in the summer shade at their St. Louis housing complex. Phillips and Deanes, 75, are co-founders of PHACTS, which stands for Pruitt-Igoe Historical Accounting, Compensation, and Truth Seeking. Their attorney, Elkin Kistner, said it would be “appropriate and necessary” for Hawley's proposal to be widened to include former Pruitt-Igoe residents. And St. Louis wasn't alone in being subjected to secretive Cold War-era testing. The area of the testing in St. Louis was described in Army documents as “a densely populated slum district.” About three-quarters of the residents were Black.

Persons: — Ben Phillips, Louis, ” Phillips, “, Phillips, Chester Deanes, Pruitt, —, inactions, Sen, Josh Hawley, Joe Biden, Elkin Kistner, Louis wasn't, Lisa Martino, Taylor, ” Deanes, ” Pruitt, Igoe, Deanes, Army “, Deane, Cori Bush, ” Organizations: LOUIS, Army, Associated Press, AP, Missouri Independent, Act, Republican U.S, Democratic, PHACTS, Democratic U.S . Rep Locations: St, Louis, ”, Pruitt, Deanes, Igoe, California, America

WASHINGTON (AP) — This probably wasn't how President Joe Biden envisioned his big foreign policy week ending. Biden on Thursday hosted Ukraine President Volodymyr Zelenskyy at the White House. "There’s no alternative.”Biden has stepped up his attacks on Trump's foreign policy record, casting the former president and his close Republican allies as lackeys for Russian President Vladimir Putin. White House national security adviser Jake Sullivan on Thursday said the U.S. has had and will continue to have “high-level” contact with New Delhi on the matter. White House press secretary Karine Jean-Pierre declined to comment Friday on the indictment.

Persons: Joe Biden, Biden, Donald Trump, Sen, Bob Menendez, Menendez, ”, Ross Baker, “, Volodymyr Zelenskyy, Zelenskyy, ” Biden, Vladimir Putin, Putin, I’ve, Hardeep Singh, Justin Trudeau, Jake Sullivan, Narendra Modi, Richard Rossow, Karine Jean, Pierre, hasn't, Nicolás Maduro's, Barack, Trump, John Feeley, Feeley, Joshua Goodman Organizations: WASHINGTON, General Assembly, Republican, Ukraine, Senate Foreign Relations, Senate Democratic, Rutgers University, White, Capitol, Republican Party, Trump, United States Congress, Vancouver . Canadian, Nijjar, House, Indian, U.S ., Center for Strategic, Independent Studies, Biden, Associated Press Locations: Canada, India, Ukraine, Russian, New Jersey, U.S, United States, Russia, New York City, Vancouver, Ottawa, New Delhi, China, Washington, Caracas, Iran, America, Havana, Nicaragua, Panama, Miami

☆ Joe Manchin’s Faux Betrayal and an Endless Green Bill of Goods
▼ + stars: | 2023-04-17 | by ( Allysia Finley | ) www.wsj.com time to read: 1 min

Who knows if West Virginia Sen. Joe Manchin truly believed the Inflation Reduction Act would reduce the deficit. Either way, he bought a green bill of goods. Several recent independent studies show that the law’s climate spending will cost trillions of dollars—many multiples more than Democrats claimed—and most of it will go to the affluent. A Goldman Sachs report last month estimated the law’s climate spending would cost $1.2 trillion over the next decade—three times as much as the Congressional Budget Office estimated last summer. One reason is the law’s sundry green-energy tax credits are uncapped, and most are available to businesses that pay little or no tax.

☆ The Next Frontier in Farming? The Ocean.
▼ + stars: | 2023-03-15 | by ( Somini Sengupta | ) www.nytimes.com time to read: +10 min

For centuries, it’s been treasured in kitchens in Asia and neglected almost everywhere else: Those glistening ribbons of seaweed that bend and bloom in cold ocean waves. Far beyond South Korea, new farms have cropped up in Maine, the Faroe Islands, Australia, even the North Sea. But even as its champions see it as a miracle crop for a hotter planet, others worry that the zeal to farm the ocean could replicate some of the same damages of farming on land. “Seaweed is not going to replace all plastic, but seaweed combined with other things can tackle single use plastic,” he said. Seaweed farms are a far cry from the rows of corn and wheat that make up monoculture farming on land.

☆ Omicron subvariants that more easily dodge immunity are causing more than 70% of U.S. infections
▼ + stars: | 2022-12-09 | by ( Spencer Kimball | ) www.cnbc.com time to read: +1 min

The most immune evasive omicron subvariants yet are now causing more than 70% of new infections in the U.S., as millions of Americans prepare to travel and gather with family for the holidays later this month. Scientists, in several independent studies, have described the BQ and XBB subvariants as more adept at evading immunity from vaccination and infection than prior versions of the virus. They pose a significant threat to people with compromised immune systems because key antibody treatments are resistant to them. The Food and Drug Administration last week pulled bebtelovimab, a monoclonal antibody used to prevent people who catch Covid from developing severe illness. Many people with weak immune systems, such as organ transplant patients, cannot take Paxlovid with their other medications.

[1/5] Women from a fishing community attend a protest against the construction of the proposed Vizhinjam Port in the southern state of Kerala, India, November 9, 2022. A $900 million project to build India’s first container transhipment port has been stalled due to protests by the region’s fishing community who believe it will destroy their livelihood. The fishing community erected the shelter after years of failed efforts to get the Kerala government to intervene while watching the coast steadily erode. "This is a matter of providing jobs to the many localities here," said Mukkola G Prabhakaran, a Kerala state council member in Modi's Bharatiya Janata Party. Accusing the Kerala state police of being "mute spectators", the Adani conglomerate has also called for federal police to be brought in.

☆ Moderna says Covid booster better against omicron BA.5, triggers immune response against BQ.1.1
▼ + stars: | 2022-11-14 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Moderna's new Covid booster triggered a stronger immune response against omicron BA.5 and also appears to work against the emerging BQ.1.1 subvariant, according to the company. Moderna, in clinical trial data published Monday, found that the new booster triggered five times more antibodies against omicron BA.5 than the old vaccines in people with prior Covid infections. Moderna said it also found the new booster triggered robust immune response against omicron BQ.1.1, an emerging Covid subvariant in the U.S. Pfizer also released data earlier this month indicating that the boosters provide better protection against omicron BA.5 than the old shots. Two independent studies from Columbia and Harvard found that the boosters did not do a much better job against omicron BA.5.

Pfizer-BioNTech's updated booster shot generates a stronger immune response against the omicron subvariants BA.4 and BA.5 compared with the original Covid vaccine, the companies said in a release Friday. Pfizer's original vaccine formula, which was first administered to older adults in December 2020, was designed to target the original coronavirus strain. The updated booster shot is designed to target the original virus strain, as well as BA.4 and BA.5, in a single shot. Two independent studies posted online late last month suggested that the updated shots do not offer better protection against the new omicron subvariants than the original vaccines do. The new findings may hint that the updated booster is better than the original vaccine, but not by much, said John Moore, a professor of microbiology and immunology at Weill Cornell Medical College.

☆ Pfizer releases more data indicating omicron boosters are better than old Covid shots
▼ + stars: | 2022-11-04 | by ( Spencer Kimball | ) www.cnbc.com time to read: +4 min

Pfizer and BioNTech also found that people with and without prior Covid infections had a significant increase in their antibody levels after the omicron boosters. Pfizer and BioNTech released more human data Friday indicating the omicron BA.5 boosters perform better than the old Covid shots. Pfizer and BioNTech released the first human data in October showing the omicron boosters trigger a better immune response. They found the new boosters and the old shots performed about the same against omicron BA.5. The scientific community and public health officials are closely following data on the boosters because the FDA authorized them without direct human data.

☆ FDA says two studies showing omicron boosters weren't much better than old Covid shots were too small to come to any conclusions
▼ + stars: | 2022-10-28 | by ( Spencer Kimball | ) www.cnbc.com time to read: +6 min

The recently authorized booster vaccine protects against the original SARS-CoV-2 virus and the more recent omicron variants, BA.4 and BA.5. The Food and Drug Administration said two studies this week showing that the new omicron boosters weren't that much better than the old shots were too small to come to any real conclusions. The antibody responses were slightly higher with the omicron boosters, though the studies concluded the difference wasn't significant. The studies are of public interest because there's very limited human data on how the omicron BA.5 boosters perform right now. The FDA also looked at data directly on the BA.5 shots that came from animal studies.

☆ Omicron subvariants resistant to key antibody treatments are increasing every week in the U.S.
▼ + stars: | 2022-10-28 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Two omicron subvariants that are resistant to key antibody treatments are on the rise in the U.S., according to data from the Centers for Disease Control and Prevention. It now represents about 50% of infections in the U.S., down from 60% the week prior, according to the data. President Joe Biden this week cautioned people with compromised immune systems that they were particularly at risk this winter because antibody treatments are not effective against emerging subvariants. Jha has said the boosters should offer better protection than the old shots because these subvariants are descended from BA.5, which is contained in the updated vaccines. "It is reasonable to expect based on what we know about immunology and the science of this virus that these new vaccines will provide better protection against infection, better protection against transmission and ongoing and better protection against serious illness," Jha told reporters in September.

Search resuls for: "Independent Studies"

12 mentions found